Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Eli Lilly Stock , LLY

921.51 -0.56 -0.06%
Pre-market 07:52:12 AM BTT
Plus500. 82% of retail CFD accounts lose money
922.07 -5.97 -0.64%
Official Close 03:59:59 PM EDT 8/16/2024 BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 08/16/2024 the closing price of the Eli Lilly share was $922.07 on BTT. Compared to the opening price on Friday 08/16/2024 on BTT of $930.71, this is a drop of 0.94%. Eli Lilly's market capitalization is $875.85 B by 950.43 M shares outstanding.
Is Eli Lilly stock a Buy, Sell or Hold? Eli Lilly stock has received a consensus rating of buy. The average rating score is and is based on 92 buy ratings, 7 hold ratings, and 0 sell ratings.
What was the 52-week low for Eli Lilly stock? The low in the last 52 weeks of Eli Lilly stock was 516.75. According to the current price, Eli Lilly is 178.33% away from the 52-week low.
What was the 52-week high for Eli Lilly stock? The high in the last 52 weeks of Eli Lilly stock was 966.32. According to the current price, Eli Lilly is 95.36% away from the 52-week high.
What are analysts forecasts for Eli Lilly stock? The 99 analysts offering price forecasts for Eli Lilly have a median target of 666.21, with a high estimate of 1,025.00 and a low estimate of 290.00. The median estimate represents a 138.32 difference from the last price of 921.51.

Eli Lilly Stock Snapshot

921.50
Bid
1.00
Bid Size
922.18
Ask
1.00
Ask Size
8/19/2024
Date
7:52 AM
Time
169.00
Volume
922.07
Prev. Close
919.94
Open
950.43 M
Number of Shares
919.94
Day Low
923.47
Day High
921.51
516.75
52 Week Low
966.32
52 Week High
921.51
4.52
Dividend in USD
0.78
Dividend Yield
100.48
P/E Ratio
89.49
Free Float in %
5.82
EPS in USD
11.35
Book Value per Share in USD
4.69
Cash Flow per Share in USD
Start Trading Futures

Historical Prices for Eli Lilly

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Eli Lilly Analyst Data

Total Analysts: 99
Buy Ratings: 92 Neutral Ratings: 7 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 290.00 Median: 666.21 Highest: 1,025.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Eli Lilly Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
07/24/24 Cantor Fitzgerald
Maintained Buy $885
07/15/24 Cantor Fitzgerald
Maintained Buy $885
07/11/24 Berenberg
Maintained Buy $1000
07/11/24 J.P. Morgan
Maintained Buy $1000
07/10/24 Barclays Capital
Maintained Buy $1025
07/05/24 Morgan Stanley
Maintained Buy $1023
07/03/24 BMO Capital Markets
Maintained Buy $1001
07/01/24 Cantor Fitzgerald
Maintained Buy $885
06/24/24 Jefferies & Company Inc.
Maintained Buy $1015
06/24/24 Bank of America Merrill Lynch
Maintained Buy $1000
06/24/24 Cantor Fitzgerald
Maintained Buy $885
06/20/24 Cantor Fitzgerald
Maintained Buy $885
06/17/24 Cantor Fitzgerald
Maintained Buy $885
06/11/24 Cantor Fitzgerald
Maintained Buy $885
06/07/24 Jefferies & Company Inc.
Maintained Buy $957
05/14/24 Argus Research Company
Maintained Buy $840
05/01/24 BMO Capital Markets
Maintained Buy $1001
05/01/24 J.P. Morgan
Maintained Buy $900
04/30/24 Cantor Fitzgerald
Maintained Buy $885
04/18/24 Cantor Fitzgerald
Maintained Buy $815
04/15/24 Cantor Fitzgerald
Maintained Buy $815
04/11/24 Goldman Sachs
Maintained Hold $723
04/05/24 Cantor Fitzgerald
Maintained Buy $815
04/02/24 Citigroup Corp.
Maintained Buy $895
04/01/24 Cantor Fitzgerald
Maintained Buy $815
03/15/24 J.P. Morgan
Maintained Buy $850
03/01/24 Bank of America Merrill Lynch
Maintained Buy $1000
02/21/24 DZ BANK
Downgraded to Buy $820
02/20/24 Cantor Fitzgerald
Maintained Buy $815
02/16/24 Morgan Stanley
Maintained Buy $950
02/14/24 Cantor Fitzgerald
Maintained Buy $815
02/07/24 Morgan Stanley
Maintained Buy $805
02/07/24 Barclays Capital
Maintained Buy $810
02/07/24 BMO Capital Markets
Maintained Buy $865
02/06/24 Wells Fargo & Co
Maintained Buy $825
02/05/24 Cantor Fitzgerald
Maintained Buy $630
02/01/24 Cantor Fitzgerald
Maintained Buy $630
01/24/24 Wells Fargo & Co
Maintained Buy $700
01/23/24 Cantor Fitzgerald
Maintained Buy $630
01/23/24 Barclays Capital
Maintained Buy $680
12/21/23 Daiwa Securities
Downgraded to Buy $610
11/20/23 Cantor Fitzgerald
Maintained Buy $630
11/15/23 Cantor Fitzgerald
Maintained Buy $630
11/09/23 Deutsche Bank
Maintained Hold $535
11/08/23 J.P. Morgan
Maintained Buy
11/03/23 Morgan Stanley
Maintained Buy $722
10/23/23 Citigroup Corp.
Maintained Buy $675
10/23/23 Cantor Fitzgerald
Maintained Buy $630
10/20/23 UBS
Maintained Buy $710
10/11/23 Morgan Stanley
Maintained Buy $673

Eli Lilly Estimates* in USD

  2024 2025 2026 2027 2028
Revenue 45,936 56,997 67,760 76,761 85,118
Dividend 5.54 6.66 7.24 7.86 8.80
Dividend Yield (in %) 0.60 % 0.72 % 0.79 % 0.85 % 0.96 %
EPS 16.19 22.27 28.93 33.73 38.70
P/E Ratio 56.84 41.32 31.80 27.28 23.77
EBIT 17,326 23,862 30,121 35,408 40,415
EBITDA 19,346 26,580 33,493 38,502 44,035
Net Profit 14,569 20,252 25,698 30,309 34,685
Net Profit Adjusted 14,569 20,252 25,698 30,309 34,685
Pre-Tax Profit 17,047 23,691 30,146 35,364 40,999
Net Profit (Adjusted) 16,931 23,320 28,595 27,290 31,030
EPS (Non-GAAP) ex. SOE 16.19 22.27 28.93 33.73 38.70
EPS (GAAP) 15.65 21.94 27.75 32.97 38.18
Gross Income 37,022 45,084 53,081 58,887 65,195
Cash Flow from Investing -5,628 -6,981 -9,977 -10,213 -11,100
Cash Flow from Operations 12,805 18,500 22,970 25,945 27,783
Cash Flow from Financing -5,628 -6,981 -9,977 -10,213 -11,100
Cash Flow per Share 13.97 21.30 26.45 33.39 44.57
Free Cash Flow 7,704 16,561 22,326 24,061 24,503
Free Cash Flow per Share 7.06 10.13 16.49 18.63 22.19
Book Value per Share 21.25 35.52 53.91 76.56 102.99
Net Debt 18,581 8,900 -5,779 -28,998 -40,001
Research & Development Exp. 11,348 12,265 14,271 15,415 16,529
Capital Expenditure 3,559 3,978 4,130 3,912 3,843
Selling, General & Admin. Exp. 8,637 9,837 10,874 11,899 12,754
Shareholder’s Equity 24,450 36,708 51,885 74,001 93,778
Total Assets 85,066 98,346 114,208 137,039 153,678
  Previous Quarter
ending 06/30/24 		Current Quarter
ending 09/30/24 		Next Quarter
ending 12/31/24 		Current Year
ending 12/31/24 		Next Year
ending 12/31/25
Earnings Estimates
No. of Analysts 16 18 18 23 24
Average Estimate 2.727 USD 4.424 USD 5.277 USD 16.186 USD 22.268 USD
Year Ago 1.960 USD -0.064 USD 2.306 USD 5.822 USD -
Publish Date 8/8/2024 10/30/2024 1/30/2025 - -
Revenue Estimates
No. of Analysts 14 16 16 21 22
Average Estimate 9,957 USD 12,125 USD 13,787 USD 45,936 USD 56,997 USD
Year Ago 8,312 USD 9,499 USD 9,353 USD 34,124 USD -
Publish Date 8/8/2024 10/30/2024 1/30/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2023 2022 2021 2020 2019 2018 2017
Sales 34,124.10 28,541.40 28,318.40 24,539.80 22,319.50 24,555.70 22,871.30
Change of sales in % 19.56 0.79 15.40 9.95 -9.11 7.36 7.77
Gross profit on sales 27,041.90 21,911.60 21,005.60 19,056.50 17,598.30 18,125.70 16,801.10
Gross profit on sales change in % 23.41 4.31 10.23 8.29 -2.91 7.88 7.93
Operating income 10,325.40 8,280.40 7,548.10 6,849.60 5,789.50 6,186.80 4,931.20
Operating income change in % 24.70 9.70 10.20 18.31 -6.42 25.46 27.38
Income before tax 6,554.60 6,806.40 6,155.50 7,229.90 5,265.90 3,795.70 2,197.40
Income before tax change in % -3.70 10.57 -14.86 37.30 38.73 72.74 -34.87
Income after tax 5,240.40 6,244.80 5,581.70 6,193.70 4,637.90 3,232.00 -204.10
Income after tax change in % -16.08 11.88 -9.88 33.55 43.50 - -

Balance Sheet in Mio. USD

2023 2022 2021 2020 2019 2018 2017
Total liabilities 53,142.60 38,714.40 39,651.20 40,807.90 36,587.00 32,999.30 33,313.10
Long-term liabilities per share 27.23 22.71 25.79 29.61 25.91 19.97 17.07
Equity 10,863.70 10,775.40 9,154.80 5,825.20 2,699.10 10,909.10 11,667.90
Equity change in % 1.15 18.61 59.16 116.41 -73.48 -15.21 -17.24
Balance sheet total 64,006.30 49,489.80 48,806.00 46,633.10 39,286.10 43,908.40 44,981.00
Balance sheet total change in % 29.33 1.40 4.66 18.70 -10.53 -2.38 15.91

Key Data in USD

2023 2022 2021 2020 2019 2018 2017
Sales per share 37.78 31.55 31.06 26.89 23.85 23.76 21.74
P/E ratio (year end quote, basic EPS) 100.48 53.00 45.12 24.87 26.52 36.97 -
P/E ratio (year end quote, diluted EPS) 100.48 53.00 45.12 24.87 26.52 36.97 -
P/E ratio (year end quote) 100.48 53.00 45.12 24.87 26.52 36.97 -
Dividend yield in % 0.78 1.07 1.23 1.75 1.96 1.94 2.46
Equity ratio in % 16.83 21.52 18.40 12.10 6.64 22.38 25.77
Debt ratio in % 83.03 78.23 81.24 87.51 93.13 75.15 74.06

Eli Lilly Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Hakim Anat 08/11/2024 14,700.00 15,779.00 n/a Sell No
JOHNSON KIMBERLY H 07/14/2024 10.00 2,664.00 950.46 Buy No
Sulzberger Gabrielle 07/14/2024 10.00 2,165.00 950.46 Buy No
Alvarez Ralph 07/14/2024 12.00 54,150.00 950.46 Buy No
LUCIANO JUAN R 07/14/2024 16.00 15,754.00 950.46 Buy No
Hedley Mary Lynne 07/14/2024 10.00 1,513.00 950.46 Buy No
LILLY ENDOWMENT INC 07/09/2024 3,500.00 96,943,810.00 944.90 Sell No
LILLY ENDOWMENT INC 07/09/2024 9,285.00 96,947,310.00 944.06 Sell No
LILLY ENDOWMENT INC 07/09/2024 4,519.00 96,956,595.00 943.09 Sell No
LILLY ENDOWMENT INC 07/09/2024 2,198.00 96,961,114.00 941.96 Sell No
LILLY ENDOWMENT INC 07/09/2024 29,147.00 96,963,312.00 940.87 Sell No
LILLY ENDOWMENT INC 07/09/2024 92,882.00 96,992,459.00 939.95 Sell No
LILLY ENDOWMENT INC 07/09/2024 28,486.00 97,085,341.00 939.11 Sell No
LILLY ENDOWMENT INC 07/09/2024 14,916.00 97,113,827.00 938.03 Sell No
LILLY ENDOWMENT INC 07/09/2024 25,067.00 97,128,743.00 936.90 Sell No
LILLY ENDOWMENT INC 07/07/2024 200.00 97,153,810.00 928.25 Sell No
LILLY ENDOWMENT INC 07/07/2024 400.00 97,154,010.00 927.30 Sell No
LILLY ENDOWMENT INC 07/07/2024 1,500.00 97,154,410.00 926.23 Sell No
LILLY ENDOWMENT INC 07/07/2024 1,585.00 97,155,910.00 924.71 Sell No
LILLY ENDOWMENT INC 07/07/2024 3,864.00 97,157,495.00 923.70 Sell No
LILLY ENDOWMENT INC 07/07/2024 5,088.00 97,161,359.00 922.61 Sell No
LILLY ENDOWMENT INC 07/07/2024 1,550.00 97,166,447.00 921.45 Sell No
LILLY ENDOWMENT INC 07/07/2024 4,446.00 97,167,997.00 920.37 Sell No
LILLY ENDOWMENT INC 07/07/2024 11,390.00 97,172,443.00 919.41 Sell No
LILLY ENDOWMENT INC 07/07/2024 18,992.00 97,183,833.00 918.35 Sell No

Eli Lilly Dividend Calendar

Date Name Dividend *yield Currency
2023 Eli Lilly 4.52 0.78 USD
2022 Eli Lilly 3.92 1.07 USD
2021 Eli Lilly 3.40 1.23 USD
2020 Eli Lilly 2.96 1.75 USD
2019 Eli Lilly 2.58 1.96 USD
2018 Eli Lilly 2.25 1.94 USD
2017 Eli Lilly 2.08 2.46 USD
2016 Eli Lilly 2.04 2.77 USD
2015 Eli Lilly 2.00 2.37 USD
2014 Eli Lilly 1.96 2.84 USD
2013 Eli Lilly 1.96 3.84 USD
2012 Eli Lilly 1.96 3.97 USD
2011 Eli Lilly 1.96 4.72 USD
2010 Eli Lilly 1.96 5.59 USD
2009 Eli Lilly 1.96 5.49 USD
2008 Eli Lilly 1.88 4.67 USD
2007 Eli Lilly 1.75 3.28 USD
2006 Eli Lilly 1.63 3.13 USD
2005 Eli Lilly 1.54 2.72 USD
2004 Eli Lilly 1.45 2.56 USD
2003 Eli Lilly 1.36 1.93 USD
2002 Eli Lilly 1.27 2.00 USD
2001 Eli Lilly 1.15 1.46 USD
2000 Eli Lilly 1.06 1.14 USD
1999 Eli Lilly 0.95 1.43 USD
*Yield of the Respective Date

Eli Lilly Calendar

Event Estimate Info Date
Earnings Report 4.424 USD Q3 2024 Earnings Release 10/30/2024
Earnings Report 5.277 USD Q4 2024 Earnings Release 01/30/2025
Earnings Report 3.580 USD Q1 2025 Earnings Release 04/24/2025
Earnings Report 4.000 USD Q2 2025 Earnings Release 08/05/2025
Earnings Report 4.700 USD Q3 2025 Earnings Release 11/04/2025

Eli Lilly Past Events

Event Actual EPS Info Date
Earnings Report 3.293 USD Q2 2024 Earnings Release 08/08/2024

Eli Lilly Profile

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
2
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Eli Lilly Shareholder

Owner in %
Freefloat 89.49
Lilly Endowment, Inc. 10.24
Lilly Endowment, Inc. 10.24
The Vanguard Group, Inc. 7.53
Vanguard Group, Inc. (Subfiler) 7.39
PNC Financial Services Group, Inc. (13F Subfiler) 5.41
State Street Corp. 3.56
Vanguard Total Stock Market ETF 2.84
Fidelity Management & Research Co. LLC 2.61
BlackRock Fund Advisors 2.53
Capital Research & Management Co. (World Investors) 2.30
Vanguard 500 Index Fund 2.16
PRIMECAP Management Co. 2.06
T Rowe Price Associates, Inc. (13F Subfiler) 2.05
BlackRock Institutional Trust Co. NA 1.91
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Eli Lilly Management

Name Job
David A. Ricks Chairman, President & Chief Executive Officer
Donald A. Zakrowski Chief Accounting Officer & Vice President-Finance
Gordon Brooks Chief Financial Officer
David Hyman Chief Medical Officer
Daniel M. Skovronsky Chief Scientific Officer & Executive VP
Robert Conley Development Leader-Neuroscience
Patrik Jonsson EVP, President-Lilly Diabetes & Obesity
Alonzo Weems Executive VP, Chief Ethics & Compliance Officer
Diogo Rau Executive VP, Chief Information & Digital Officer
Eric Dozier Executive VP-Human Resources & Diversity
Jacob S. van Naarden Executive Vice President
Melissa Seymour Executive Vice President-Global Quality
Anne E. White Executive Vice President-Lilly Neuroscience
Jennifer Oleksiw Global Chief Customer Officer & Vice President
Kim Macko Head-Global Brand Development
Katherine Baicker Independent Director
Gabrielle G. Greene-Sulzberger Independent Director
Kimberly H. Johnson Independent Director
Ralph Alvarez Independent Director
Marschall S. Runge Independent Director
Jon Erik Fyrwald Independent Director
Jamere Jackson Independent Director
Karen Walker Independent Director
Mary Lynne Hedley Independent Director
William G. Kaelin Independent Director
Joe Fletcher Investor Relations Contact
Juan Ricardo Luciano Lead Independent Director
Edgardo Hernandez President-Manufacturing Operations & Senior VP
Anat Hakim Secretary, Executive VP & General Counsel
Andy Vicari Senior Director & US Brand Leader-Insulins
Ilya Yuffa Senior VP & President-Lilly Bio Medicines
Mark Genovese Senior Vice President-Immunology Development
Travis Coy VP, Head-Transactions & Business Development
Christian Nguyen VP-Global Patient Outcomes & Real World Evidence
Laura A. Lane Vice President
Ruth Gimeno Vice President
Robert J. Heine Vice President-Medical Affairs
Nathaniel R. Miles Vice President-Strategic Initiatives